Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) sets new 52-week low at $23.19

0

Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) hit a new 52-week low during midday trading on Tuesday. The stock traded as low as $23.19 and last traded at $23.42, with a volume of 5,313 shares traded in hands. The stock previously closed at $23.71.

Several brokerages have published reports on FMS. StockNews.com upgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong buy” rating in a Friday, July 1 research note. JPMorgan Chase & Co. raised its price target on Fresenius Medical Care AG & Co. KGaA from €48.70 ($48.70) to €51.00 ($51.00) and assigned the company a rating “underweight” in a Thursday, May 5, report. Jefferies Financial Group upgraded Fresenius Medical Care AG & Co. KGaA from an “underperforming” rating to a “buy” rating and raised its target price for the company from $30.30 to $33.70 in a report Monday, June 27. Truist Financial lowered its price target on Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “holding” rating for the company in a Wednesday, June 22 report. Finally, Berenberg Bank lowered its price target on Fresenius Medical Care AG & Co. KGaA from €84.90 ($84.90) to €83.40 ($83.40) in a Thursday, March 17 report. One financial analyst has assigned the stock a sell rating, six have assigned a hold rating, four have issued a buy rating and one has assigned the company’s stock a high buy rating. According to data from MarketBeat, Fresenius Medical Care AG & Co. KGaA currently has a consensus rating of “Hold” and an average price target of $52.51.

The company has a 50-day moving average price of $27.41 and a 200-day moving average price of $30.99. The company has a market capitalization of $13.60 billion, a price/earnings ratio of 13.26, a P/E/G ratio of 0.97 and a beta of 1.21. The company has a current ratio of 1.26, a quick ratio of 0.93 and a debt ratio of 0.51.

Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) last reported results on Wednesday, May 4. The company reported earnings per share (EPS) of $0.38 for the quarter, beating consensus analyst estimates of $0.30 by $0.08. The company posted revenue of $5.10 billion in the quarter, versus analyst estimates of $4.97 billion. Fresenius Medical Care AG & Co. KGaA achieved a return on equity of 6.99% and a net margin of 4.91%. On average, analysts expect Fresenius Medical Care AG & Co. KGaA to post 1.98 earnings per share for the current year.

The company also recently announced an annual dividend, which was paid on Friday, May 27. Shareholders of record on Monday, May 16 received a dividend of $0.7093. The ex-dividend date was Friday, May 13. This represents a dividend yield of 3.4%. The payout ratio of Fresenius Medical Care AG & Co. KGaA is currently 28.00%.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Pzena Investment Management LLC increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 22.4% in the first quarter. Pzena Investment Management LLC now owns 11,577,632 shares of the company worth $389,935,000 after acquiring 2,118,186 additional shares in the last quarter. First Trust Advisors LP increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 15.1% in the fourth quarter. First Trust Advisors LP now owns 1,925,326 shares of the company worth $62,496,000 after acquiring an additional 252,768 shares in the last quarter. Cambiar Investors LLC increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 18.3% in the first quarter. Cambiar Investors LLC now owns 1,363,874 shares of the company worth $45,935,000 after acquiring an additional 210,819 shares in the last quarter. Bank of America Corp DE increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 27.9% in the first quarter. Bank of America Corp DE now owns 1,083,689 shares of the company worth $36,499,000 after acquiring 236,459 additional shares in the last quarter. Finally, Invesco Ltd. increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 21.2% in the first quarter. Invesco Ltd. now owns 456,009 shares of the company worth $15,358,000 after acquiring an additional 79,836 shares in the last quarter. 4.73% of the shares are currently held by institutional investors and hedge funds.

About Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMS)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

Featured articles



Get news and reviews for Fresenius Medical Care AG & Co. KGaA Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com’s free daily email newsletter .

Share.

Comments are closed.